Rationale: Some reports indicate longitudinal variability in sputum differential cell counts, whereas others describe stability. Highly variable sputum eosinophil percentages are associated with greater lung function loss than persistently elevated eosinophil percentages, but elevated neutrophils are linked to more severe asthma. Objectives: To examine sputum granulocyte stability or variability longitudinally and associations with important clinical characteristics. Methods: The SARP III (Severe Asthma Research Program III) cohort underwent comprehensive phenotype characterization at baseline and annually over 3 years. Adult subjects with acceptable sputum levels were assigned to one of three longitudinal sputum groups: eosinophils predominantly <2%, eosinophils predominantly ≥2%, or highly variable eosinophil percentages (>2 SDs determined from independent, repeated baseline eosinophil percentages). Subjects were similarly assigned to one of three longitudinal neutrophil groups with a 50% cut point.Measurements and Main Results: The group with predominantly <2% sputum eosinophils had the highest lung function (prebronchodilator FEV1% predicted, P < 0.01; FEV1/FVC ratio, P < 0.001) at baseline and throughout 3 years compared with other eosinophil groups. Healthcare use did not differ, although the highly variable eosinophil group reported more asthma exacerbations at Year 3. Longitudinal neutrophil groups showed few differences. However, a combination of predominantly ≥2% eosinophil and ≥50% neutrophil groups resulted in the lowest prebronchodilator FEV1% predicted (P = 0.049) compared with the combination with predominantly <2% eosinophils and<50% neutrophils.Conclusions: Subjects with predominantly ≥2% sputum eosinophils in combination with predominantly ≥50% neutrophils showed greater loss of lung function, whereas those with highly variable sputum eosinophils had greater healthcare use.
Rationale: Some reports indicate longitudinal variability in sputum differential cell counts, whereas others describe stability. Highly variable sputum eosinophil percentages are associated with greater lung function loss than persistently elevated eosinophil percentages, but elevated neutrophils are linked to more severe asthma. Objectives: To examine sputum granulocyte stability or variability longitudinally and associations with important clinical characteristics. Methods: The SARP III (Severe Asthma Research Program III) cohort underwent comprehensive phenotype characterization at baseline and annually over 3 years. Adult subjects with acceptable sputum levels were assigned to one of three longitudinal sputum groups: eosinophils predominantly <2%, eosinophils predominantly ≥2%, or highly variable eosinophil percentages (>2 SDs determined from independent, repeated baseline eosinophil percentages). Subjects were similarly assigned to one of three longitudinal neutrophil groups with a 50% cut point.Measurements and Main Results: The group with predominantly <2% sputum eosinophils had the highest lung function (prebronchodilator FEV1% predicted, P < 0.01; FEV1/FVC ratio, P < 0.001) at baseline and throughout 3 years compared with other eosinophil groups. Healthcare use did not differ, although the highly variable eosinophil group reported more asthma exacerbations at Year 3. Longitudinal neutrophil groups showed few differences. However, a combination of predominantly ≥2% eosinophil and ≥50% neutrophil groups resulted in the lowest prebronchodilator FEV1% predicted (P = 0.049) compared with the combination with predominantly <2% eosinophils and<50% neutrophils.Conclusions: Subjects with predominantly ≥2% sputum eosinophils in combination with predominantly ≥50% neutrophils showed greater loss of lung function, whereas those with highly variable sputum eosinophils had greater healthcare use.
Authors: Mohammed T Al-Samri; Andrea Benedetti; David Préfontaine; Ron Olivenstein; Catherine Lemière; Parameswaran Nair; James G Martin; Qutayba Hamid Journal: J Allergy Clin Immunol Date: 2010-04-14 Impact factor: 10.793
Authors: Annette T Hastie; Wendy C Moore; Deborah A Meyers; Penny L Vestal; Huashi Li; Stephen P Peters; Eugene R Bleecker Journal: J Allergy Clin Immunol Date: 2010-04-15 Impact factor: 10.793
Authors: Annette T Hastie; David T Mauger; Loren C Denlinger; Andrea Coverstone; Mario Castro; Serpil Erzurum; Nijar Jarjour; Bruce D Levy; Deborah A Meyers; Wendy C Moore; Brenda Phillips; Sally E Wenzel; John V Fahy; Elliot Israel; Eugene R Bleecker Journal: J Allergy Clin Immunol Date: 2020-02-05 Impact factor: 10.793
Authors: Michael C Peters; Sheena Kerr; Eleanor M Dunican; Prescott G Woodruff; Merritt L Fajt; Bruce D Levy; Elliot Israel; Brenda R Phillips; David T Mauger; Suzy A Comhair; Serpil C Erzurum; Mats W Johansson; Nizar N Jarjour; Andrea M Coverstone; Mario Castro; Annette T Hastie; Eugene R Bleecker; Sally E Wenzel; John V Fahy Journal: J Allergy Clin Immunol Date: 2018-03-07 Impact factor: 10.793
Authors: Sophie F Demarche; Florence N Schleich; Virginie A Paulus; Monique A Henket; Thierry J Van Hees; Renaud E Louis Journal: J Allergy Clin Immunol Pract Date: 2017-04-25
Authors: W Gerald Teague; Brenda R Phillips; John V Fahy; Sally E Wenzel; Anne M Fitzpatrick; Wendy C Moore; Annette T Hastie; Eugene R Bleecker; Deborah A Meyers; Stephen P Peters; Mario Castro; Andrea M Coverstone; Leonard B Bacharier; Ngoc P Ly; Michael C Peters; Loren C Denlinger; Sima Ramratnam; Ronald L Sorkness; Benjamin M Gaston; Serpil C Erzurum; Suzy A A Comhair; Ross E Myers; Joe Zein; Mark D DeBoer; Anne-Marie Irani; Elliot Israel; Bruce Levy; Juan Carlos Cardet; Wanda Phipatanakul; Jonathan M Gaffin; Fernando Holguin; Merritt L Fajt; Shean J Aujla; David T Mauger; Nizar N Jarjour Journal: J Allergy Clin Immunol Pract Date: 2017-08-31
Authors: M Kupczyk; B Dahlén; P J Sterk; E Nizankowska-Mogilnicka; A Papi; E H Bel; P Chanez; P H Howarth; S T Holgate; G Brusselle; N M Siafakas; M Gjomarkaj; S-E Dahlén Journal: Allergy Date: 2014-07-08 Impact factor: 13.146
Authors: T Zaihra; C J Walsh; S Ahmed; C Fugère; Q A Hamid; R Olivenstein; J G Martin; A Benedetti Journal: BMC Pulm Med Date: 2016-05-10 Impact factor: 3.317
Authors: Matthew J Loza; Ratko Djukanovic; Kian Fan Chung; Daniel Horowitz; Keying Ma; Patrick Branigan; Elliot S Barnathan; Vedrana S Susulic; Philip E Silkoff; Peter J Sterk; Frédéric Baribaud Journal: Respir Res Date: 2016-12-15
Authors: Ji Young Kim; Patrick Stevens; Manjula Karpurapu; Hyunwook Lee; Joshua A Englert; Pearlly Yan; Tae Jin Lee; Navjot Pabla; Maciej Pietrzak; Gye Young Park; John W Christman; Sangwoon Chung Journal: Front Immunol Date: 2022-07-26 Impact factor: 8.786